Get the Stockscreener App
2.71
0.74%
0.02
After Hours:
2.71
Atea Pharmaceuticals Inc stock is traded at $2.71, with a volume of 326.63K.
It is up +0.74% in the last 24 hours and down -7.19% over the past month.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
See More
Previous Close:
$2.69
Open:
$2.7
24h Volume:
326.63K
Relative Volume:
1.01
Market Cap:
$231.77M
Revenue:
$351.37M
Net Income/Loss:
$-174.01M
P/E Ratio:
-1.3092
EPS:
-2.07
Net Cash Flow:
$-126.94M
1W Performance:
-2.87%
1M Performance:
-7.19%
6M Performance:
-22.13%
1Y Performance:
-29.61%
1-Day Range:
$2.63
$2.7365
1-Week Range:
$2.60
$2.9732
52-Week Range:
$2.60
$4.145
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Name
Atea Pharmaceuticals Inc
Sector
Industry
Phone
857-204-8109
Address
225 FRANKLIN STREET, BOSTON
Compare AVIR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
2.71 | 231.77M | 351.37M | -174.01M | -126.94M | -2.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.22 | 122.24B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.18 | 59.73B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.94 | 35.43B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
237.77 | 30.77B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
96.52 | 23.20B | 3.30B | -501.07M | 1.03B | -2.1146 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-10-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-06-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-18-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-25-20 | Initiated | Evercore ISI | Outperform |
| Nov-24-20 | Initiated | JP Morgan | Overweight |
| Nov-24-20 | Initiated | Morgan Stanley | Overweight |
| Nov-24-20 | Initiated | William Blair | Outperform |
View All
Atea Pharmaceuticals Inc Stock (AVIR) Latest News
Atea Pharmaceuticals Doses First Patient In Phase 3 Trial For Chronic Hepatitis C Treatment - RTTNews
Atea Pharmaceuticals Doses First Patient in Late-Stage Study of Hepatitis C Virus Combination Regimen - MarketScreener
Atea Pharmaceuticals Announces Dosing of First Patient in - GlobeNewswire
Atea Pharmaceuticals Announces Dosing Of First Patient In C-Beyond, Phase 3 Study Evaluating Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus - MarketScreener
Breakthrough: Atea's New 8-Week Hepatitis C Treatment Enters Final Trial Stage - Stock Titan
Layoff Tracker: Spark Lays Off 298 Employees - BioSpace
HighTower Advisors LLC Purchases Shares of 50,087 Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals board nominee withdrawal ahead of 2025 meeting By Investing.com - Investing.com South Africa
Atea Pharmaceuticals board nominee withdrawal ahead of 2025 meeting - Investing.com
Driver Notifies Atea Pharmaceuticals of Withdrawal of Notice of Nomination - The Manila Times
Charles Schwab Investment Management Inc. Boosts Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals takes steps to boost shareholder value By Investing.com - Investing.com South Africa
Atea Pharmaceuticals takes steps to boost shareholder value - Investing.com
Atea Pharma Reviewing Strategic Opportunities After Cutting 25% of Jobs - MarketWatch
Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value - GlobeNewswire
Atea's Bold Restructuring: $15M Cost Savings Plan and Strategic Review Unveiled - Stock Titan
Atea Shareholder Seeks Board Change, Plans to Nominate Directors at 2025 Annual Meeting - Marketscreener.com
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors - MarketScreener
Connor Clark & Lunn Investment Management Ltd. Raises Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals Issues Statement Regarding Director Nominations - GlobeNewswire
Atea Pharmaceuticals receives notice of director nominations from Bradley Radoff -March 21, 2025 at 05:58 pm EDT - MarketScreener
Major Shake-up Looms: Activist Investor Challenges Atea Pharmaceuticals Board Control - StockTitan
Atea Pharmaceuticals, Inc. (AVIR): A Bull Case Theory - Insider Monkey
Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025 - GlobeNewswire
Major Breakthrough: Atea's New Hepatitis C Drug Enters Final Testing with Shorter Treatment Time - StockTitan
Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - insights.citeline.com
Earnings call transcript: Atea Pharmaceuticals Q4 2024 results weigh on stock - Investing.com Australia
What is William Blair’s Forecast for AVIR Q1 Earnings? - Defense World
William Blair Reaffirms “Outperform” Rating for Atea Pharmaceuticals (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals Faces Challenges Amid Workforce Reductions and Cost-Cutting Efforts - MSN
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2024 Earnings Call Transcript - Insider Monkey
BML Capital Management LLC Has $25.49 Million Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - MarketBeat
Atea Pharmaceuticals’ Promising Earnings Call Highlights - TipRanks
Atea Pharma Cuts Workforce By 25%, Expects $15 Million In Cost Savings, Plans Phase 3 Hepatitis C Trial - Benzinga
Atea Pharmaceuticals Advances HCV Program with FDA Approval - TipRanks
Atea Pharmaceuticals Cuts Workforce by 25% - MarketWatch
Atea Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Atea Pharmaceuticals reports Q4 EPS (40c), consensus (29c) - TipRanks
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides - The Bakersfield Californian
Can Atea's 98% Effective HCV Drug Reshape the $3B Market? FDA Says Yes to Phase 3 - StockTitan
Atea Pharmaceuticals Inc (AVIR) Q4 2024 Earnings Call Highlights: Strategic Moves and Promising ... By GuruFocus - Investing.com Canada
Atea Pharmaceuticals (AVIR) Expected to Announce Quarterly Earnings on Thursday - Defense World
AVIRAtea Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Atea Pharmaceuticals Inc Stock (AVIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):